Literature DB >> 9636585

Risk and benefit of antibody induction therapy in combination with tacrolimus immunosuppression after liver transplantation.

J Klupp1, W O Bechstein, J Pratschke, S G Tullius, A Gebhard, H Lobeck, J M Langrehr, R Neuhaus, P Neuhaus.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9636585     DOI： 10.1016/s0041-1345(98)00308-x

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  3 in total

1.  Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation.

Authors:  G L Plosker; R H Foster
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

Review 2.  Maintenance immunosuppression for adults undergoing liver transplantation: a network meta-analysis.

Authors:  Manuel Rodríguez-Perálvarez; Marta Guerrero-Misas; Douglas Thorburn; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2017-03-31

3.  Induction immunosuppression in adults undergoing liver transplantation: a network meta-analysis.

Authors:  Lawrence Mj Best; Jeffrey Leung; Suzanne C Freeman; Alex J Sutton; Nicola J Cooper; Elisabeth Jane Milne; Maxine Cowlin; Anna Payne; Dana Walshaw; Douglas Thorburn; Chavdar S Pavlov; Brian R Davidson; Emmanuel Tsochatzis; Norman R Williams; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2020-01-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.